Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. (HMTXF) is an autologous stem cell therapy company that has developed a blood-based stem cell therapeutics platform, including angiogenic cell precursors. The company's recent achievements include the successful publication of several peer-reviewed studies on the efficacy of ACP-01 in treating heart disease and chronic limb-threatening ischemia. With a focus on regenerative and cardiac function improvement, Hemostemix aims to provide breakthrough treatments for cardiovascular patients through cutting-edge stem cell therapies.
Hemostemix announced it has been granted the trademark 'Your Fountain of Youth' by the Swiss Trademark Office, a significant milestone for the company's intellectual property portfolio.
CEO Thomas Smeenk highlighted the positive results from ACP-01, their cardiovascular treatment, with a 27% improvement in LVEF% and notable reductions in ulcer size, amputation, and mortality rates in clinical trials.
Additionally, Hemostemix will make a 2023 interest payment of $226,688.25 to debenture holders via 2,229,616 shares at $0.101671 per share, subject to regulatory approval and a four-month hold period under Canadian securities laws.
Hemostemix announced a strategic partnership with CytoImmune Therapeutics to re-establish ACP-01 production at CytoImmune's facility in Puerto Rico. The company secured $1,800,000 in financing commitments through a private placement at $0.05 per unit. CytoImmune will subscribe for $1,370,000 worth of these units. The partnership aims to scale production of ACP-01, a treatment for chronic limb-threatening ischemia (CLTI), potentially reaching sales of $2 million per month by 2025. Hemostemix's phase II clinical trial showed promising results, with 83% of patients experiencing ulcer healing and pain cessation. The proceeds of the financing will be used for initial batch processing and working capital.
FAQ
What does Hemostemix specialize in?
What recent achievements has Hemostemix had?
What is the focus of Hemostemix's treatments?
